Sumitomo Dainippon Pharma Co (DPM) Stock Statistics & Valuation Metrics

Sumitomo Dainippon Pharma Co has a market cap or net worth of EUR 4.79B. The enterprise value is EUR 791.57B.

Market Cap

EUR 4.79B

Enterprise Value

EUR 791.57B

Sumitomo Dainippon Pharma Co has 449,204,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

449,204,560

Owned by Insiders

―

Owned by Institutions

6.14%

Sumitomo Dainippon Pharma Co’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 8.81%.

Return on Equity (ROE)

0.37

Return on Assets (ROA)

0.13

Return on Invested Capital (ROIC)

8.81%

Return on Capital Employed (ROCE)

0.09

Revenue Per Employee

145.15M

Profits Per Employee

34.22M

Employee Count

3,123

Asset Turnover

0.56

Inventory Turnover

2.30

The current PE Ratio of Sumitomo Dainippon Pharma Co is 6.74. Sumitomo Dainippon Pharma Co’s PEG ratio is 0.01.

PE Ratio

6.74

PS Ratio

1.78

PB Ratio

2.01

Price to FCF

13.93

Price to Operating Cash Flow

12.73

PEG Ratio

0.01

In the last 12 months, Sumitomo Dainippon Pharma Co had revenue of 453.29B and earned 106.86B in profits. Earnings per share was 268.99.

Revenue

453.29B

Gross Profit

256.89B

Operating Income

50.34B

Pretax Income

100.34B

Net Income

106.86B

EBITDA

131.32B

Earnings Per Share (EPS)

268.99

In the last 12 months, operating cash flow was 70.36B and capital expenditures -2.83B, giving a free cash flow of 67.54B billion.

Operating Cash Flow

70.36B

Free Cash Flow

67.54B

Free Cash Flow per Share

139.26

Sumitomo Dainippon Pharma Co pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

7.99%

Earnings Yield

5.48%

Beta

1.29

52-Week Price Change

15.91%

50-Day Moving Average

8.98

200-Day Moving Average

9.46

Relative Strength Index (RSI)

66.25

Average Volume (3m)

200

Sumitomo Dainippon Pharma Co upcoming earnings date is Jan 29, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 30, 2026

Next Earnings Date

Jan 29, 2027

Ex-Dividend Date

―

Sumitomo Dainippon Pharma Co as a current ratio of 1.03, with Debt / Equity ratio of 74.26%

Current Ratio

1.03

Quick Ratio

0.71

Debt to Market Cap

0.26

Net Debt to EBITDA

1.32

Interest Coverage Ratio

4.94

In the past 12 months, Sumitomo Dainippon Pharma Co has paid -6.52B in taxes.

Income Tax

-6.52B

Effective Tax Rate

-0.06

Sumitomo Dainippon Pharma Co EV to EBITDA ratio is 12.31, with an EV/FCF ratio of 13.43.

EV to Sales

1.84

EV to EBITDA

12.31

EV to Free Cash Flow

13.43

EV to Operating Cash Flow

12.89

Sumitomo Dainippon Pharma Co has EUR 77.76B in cash and marketable securities with EUR 139.69B in debt, giving a net cash position of -EUR 61.93B billion.

Cash & Marketable Securities

EUR 77.76B

Total Debt

EUR 139.69B

Net Cash

-EUR 61.93B

Net Cash Per Share

-EUR 137.87

Tangible Book Value Per Share

EUR 155.06

Gross margin is 54.99%, with operating margin of 10.05%, and net profit margin of 23.73%.

Gross Margin

54.99%

Operating Margin

10.05%

Pretax Margin

22.47%

Net Profit Margin

23.73%

EBITDA Margin

27.78%

EBIT Margin

23.47%

The average price target for Sumitomo Dainippon Pharma Co is EUR 15.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 15.29

Price Target Upside

40.35% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

-0.25%

EPS Growth Forecast

-74.88%